Ishara Investments LP Acquires New Stake in Xeris Biopharma Holdings, Inc. $XERS

Ishara Investments LP acquired a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the 4th quarter, HoldingsChannel reports. The firm acquired 800,000 shares of the company’s stock, valued at approximately $6,280,000. Xeris Biopharma accounts for about 7.3% of Ishara Investments LP’s investment portfolio, making the stock its 2nd largest holding.

Several other institutional investors have also bought and sold shares of XERS. UBS Group AG lifted its position in shares of Xeris Biopharma by 682.4% during the third quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock worth $14,511,000 after acquiring an additional 1,554,869 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Xeris Biopharma by 13.8% during the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after acquiring an additional 1,358,760 shares in the last quarter. Qube Research & Technologies Ltd lifted its position in shares of Xeris Biopharma by 67.5% during the second quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock worth $14,429,000 after acquiring an additional 1,245,188 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after acquiring an additional 1,199,435 shares in the last quarter. Finally, Granahan Investment Management LLC lifted its position in shares of Xeris Biopharma by 249.4% during the fourth quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company’s stock worth $9,604,000 after acquiring an additional 873,236 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Stock Performance

NASDAQ:XERS opened at $6.90 on Thursday. The company has a market cap of $1.19 billion, a P/E ratio of 115.00 and a beta of 0.78. The stock’s fifty day moving average price is $6.24 and its two-hundred day moving average price is $6.57. Xeris Biopharma Holdings, Inc. has a 1 year low of $4.40 and a 1 year high of $10.08. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%.The company had revenue of $83.13 million for the quarter, compared to the consensus estimate of $79.83 million. As a group, analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Insider Buying and Selling

In related news, Director Marla Persky sold 15,500 shares of the stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $5.90, for a total value of $91,450.00. Following the sale, the director owned 126,500 shares in the company, valued at approximately $746,350. This trade represents a 10.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total value of $97,440.00. Following the completion of the sale, the director owned 126,500 shares in the company, valued at $770,385. This trade represents a 11.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 127,335 shares of company stock valued at $766,733 in the last ninety days. 4.35% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

XERS has been the topic of several recent research reports. Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Xeris Biopharma in a research report on Monday, March 2nd. Finally, Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.